- CITATIONS: 2
|Application ||WB, IHC-P, IF, E|
|Calculated MW||42344 Da|
|Antigen Region||342-371 aa|
|Other Names||Serine/threonine-protein kinase 17B, DAP kinase-related apoptosis-inducing protein kinase 2, STK17B, DRAK2|
|Target/Specificity||This DRAK2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 342-371 amino acids from the C-terminal region of human DRAK2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Precautions||DRAK2 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Phosphorylates myosin light chains (By similarity). Acts as a positive regulator of apoptosis.|
|Cellular Location||Nucleus. Cell membrane. Endoplasmic reticulum-Golgi intermediate compartment. Note=Colocalizes with STK17B at the plasma membrane.|
|Tissue Location||Highly expressed in placenta, lung, pancreas. Lower levels in heart, brain, liver, skeletal muscle and kidney|
Provided below are standard protocols that you may find useful for product applications.
DRAK2 is a novel serine/threonine kinase that induces apoptosis via catalytic activity. DRAKs present high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases. DRAK2 is located in nucleus, and the messenger RNA is ubiquitously expressed in human tissues.
Sanjo, H., et al., J. Biol. Chem. 273(44):29066-29071 (1998).
If you have any additional inquiries please email technical services at email@example.com.